Stock Reports

HYBE’s Target Price Rises to 330,000 Won on the Back of BTS’s Successful Concerts and Music Sales—NH

Kim Hyung-il
2026-07-29 08:03:45
[Edaily Reporter Kim Hyung-il ] NH INVESTMENT & SECURITIES assessed that HYBE(352820)’s mid- to long-term growth drivers—including the rapid growth of Cortis’s fanbase and the expansion of global music sales centered on BTS and KATSEYE—are not yet fully reflected in the company’s market value. Accordingly, the firm raised its target price from 310,000 won to 330,000 won and maintained its “Buy (BUY)” investment rating.

(Source: NH INVESTMENT & SECURITIES)


On the 29th, Lee Hwa-jeong, an analyst at NH INVESTMENT & SECURITIES, stated, “Revenue growth driven by BTS’s concerts, merchandise (MD) sales, and the success of their music releases continues,” adding, “The upward trend in unit prices and demand across all revenue streams will serve as mid- to long-term growth drivers.”

HYBE recorded revenue of 1.4 trillion won and operating profit of 170.9 billion won in the second quarter of this year, marking year-over-year increases of 106% and 159%, respectively, and achieving an “earnings surprise” that exceeded market expectations. In particular, concert revenue reached a record high of 647.7 billion won, driven by higher ticket prices and increased ticket sales. The share of concert revenue in total revenue also reached 45%, significantly exceeding market expectations and driving overall growth.

The analyst explained, “Although concert revenue has a higher cost ratio compared to digital music or merchandise, its absolute contribution to profits remained robust thanks to overall revenue growth, even as the share of concert revenue expanded,” adding, “The increase in company-wide personnel expenses was largely due to the recognition of incentive provisions resulting from strong performance.”

He continued, “With the expansion of BTS’s concert and merchandise sales, coupled with the growth of the global music market and the expansion of Cortis’s fanbase, the company’s medium- to long-term growth trend is expected to continue,” adding, “The current stock price does not fully reflect this growth potential.”

Economy

Corporation

IT·Science

Economy

"AI Broadcasts on Its Own"... A Creator Startup Founded by a Former TikTok Employee [VC Cradle]

A virtual creator that doesn’t require a human actor has emerged. There is no pre-written script, nor is there an operator manipulating it in real time. Artificial intelligence (AI) hosts the broadcas…
2026-08-08 11:01:04

Corporation

Mezzion Pharma Co., Ltd. Simultaneously Improves Cysts and Kidney Function in ADPKD… “Moving Directly to Phase 2b Clinical Trials in Korea and the U.S.”

“When you examine the kidneys of mice with polycystic kidney disease, you can see large cysts. However, after administering Udenafil, a reduction in the size of these cysts was visible even to the nak…
2026-08-08 08:16:01

IT·Science

SK BIOPHARMACEUTICALS Soars on Cenobamate Growth… The Era of 45% Generic Drug Prices Begins [Weekly Bio Roundup]

(Graphic: Generative AI) During the first week of August (August 3–7), SK BIOPHARMACEUTICALS posted its best-ever quarterly earnings, driven by the growth of its new epilepsy drug “cenobamate.” Ad…
2026-08-08 08:31:03